While the company did not provide specific reasons for the halt, Gilead Sciences said it is “reviewing the benefit-risk” of its anti-CD47 antibody magrolimab across all ongoing trials.
Tag Archive for: solid tumors
Amid falling COVID-19 revenues, Pfizer continues to invest in antibody-drug conjugates in a deal with Nona Biosciences worth $1 billion as its $43 billion Seagen buy closed on Thursday.
Following a year of transformation, Novartis is laser-focused on its goals.
The biotech has acquired an exclusive global license for Shanghai-based DualityBio’s investigational antibody-drug conjugate for select solid tumors.
AstraZeneca said on Monday a mid-stage trial of its cancer drug Enhertu showed positive results across multiple HER2-expressing advanced solid tumors in heavily pre-treated patients.
Genome engineering company Replay and The University of Texas’ MD Anderson Cancer Center have joined forces to launch Syena, an oncology product company.
Merck and New Jersey-based Nectin Therapeutics announced a research collaboration agreement Tuesday to study the safety and efficacy of Nectin’s investigational antibody NTX1088 in locally advanced and metastatic solid tumors.
AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.
AstraZeneca and Neogene have entered into a definitive acquisition agreement in which AstraZeneca will buy all outstanding equity in the smaller company for $320 million.